Johnson & Johnson
BASE:JNJD Stock Report
Johnson & Johnson Balance Sheet Health
Financial Health criteria checks 4/6 Johnson & Johnson has a total shareholder equity of $70.2B and total debt of $35.8B, which brings its debt-to-equity ratio to 51%. Its total assets and total liabilities are $178.3B and $108.1B respectively. Johnson & Johnson's EBIT is $23.1B making its interest coverage ratio -35.9. It has cash and short-term investments of $20.3B.
Key information
51.0%
Debt to equity ratio
Interest coverage ratio -35.9x Cash US$20.30b Equity US$70.16b Total liabilities US$108.13b Total assets US$178.29b
Recent financial health updates
Show all updates Johnson & Johnson Announces U.S. Food and Drug Administration Grants Nipocalimab Breakthrough Therapy Designation for the Treatment of Adults Living with Moderate-To-Severe Sjogren's Disease Nov 12
Johnson & Johnson Submits Applications in the U.S. and EU Seek Approval of DARZALEX FASPRO® as Subcutaneous Monotherapy for High-Risk Smoldering Multiple Myeloma Nov 08
Johnson & Johnson Announces Results from Phase 3 GRAVITI Study of Tremfya Oct 29
Johnson & Johnson Highlights Innovative Neuropsychiatry Portfolio and Pipeline at Psych Congress Oct 26
Johnson & Johnson Announces New Spectrem Study Findings Reveal Tremfya (Guselkumab) Effectively Clears Overlooked and Undertreated Plaque Psoriasis Oct 25
Connecticut Jury Delivers $15 Million Asbestos Verdict Against Johnson & Johnson Oct 16
Johnson & Johnson Announces Positive Results from the Phase 2/3 Vibrance-MG Study of Nipocalimab Johnson & Johnson Announces Tremfya Data in Both Crohn's Disease and Ulcerative Colitis Oct 10
Johnson & Johnson Announces the Results of A Landmark Real-World, Head-To-Head Study Showing That Erleada (Apalutamide) Oct 03
Johnson & Johnson Files for U.S. FDA Approval of DARZALEX FASPRO-Based Quadruplet Regimen for Newly Diagnosed Multiple Myeloma Patients for Whom Transplant Is Not Planned Oct 01
Johnson & Johnson Announces Data from Three Studies Highlighting Clinical Efficacy of Darzalex® (Daratumumab) and Darzalex Faspro in Maintenance Regimens Johnson & Johnson Announces Interim Data from the Ongoing Phase 2 Sunrise-4 Study Showing Neoadjuvant Treatment with Investigational Tar-200 Plus Cetrelimab Johnson & Johnson Announces Updated Results from the Phase 3 Mariposa-2 Study Which Showed Rybrevant (Amivantamab-Vmjw) Sep 14
Johnson & Johnson Announces the Retirement of D. S. Davis as Director and Committee Changes Sep 11
Johnson & Johnson to Report Q4, 2024 Results on Jan 22, 2025 Sep 06
Johnson & Johnson Seeks First Approval of Nipocalimab to Treat Broadest Population Living with Antibody Positive Generalized Myasthenia Gravis Aug 29
Johnson & Johnson Announces Executive Changes Aug 26
Johnson & Johnson Announces U.S. Food and Drug Administration Approves Rybrevant® (Amivantamab-Vmjw) Plus Lazcluze™ (Lazertinib) Aug 20
Johnson & Johnson Announces Results from the Phase 2 Open-Label UNITY Study of Nipocalimab for the Treatment of Alloimmunized Pregnant Individuals Aug 08
Johnson & Johnson Announces Darzalex Faspro® (Daratumumab and Hyaluronidase-Fihj)-Based Quadruplet Regimen Approved in the U.S. for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible Aug 01
Johnson & Johnson Seeks U.S. FDA Approval of Spravato (Esketamine) as the First and Only Monotherapy for Adults with Treatment-Resistant Depression Jul 22
Johnson & Johnson Announces Quarterly Cash Dividend for Third Quarter of 2024, Payable on September 10, 2024 Jul 17
Financial Position Analysis
Short Term Liabilities: JNJD's short term assets ($53.2B) exceed its short term liabilities ($51.8B).
Long Term Liabilities: JNJD's short term assets ($53.2B) do not cover its long term liabilities ($56.4B).
Debt to Equity History and Analysis
Debt Level: JNJD's net debt to equity ratio (22%) is considered satisfactory .
Reducing Debt: JNJD's debt to equity ratio has increased from 50.2% to 51% over the past 5 years.
Debt Coverage: JNJD's debt is well covered by operating cash flow (70.3%).
Interest Coverage: JNJD earns more interest than it pays, so coverage of interest payments is not a concern.
Discover healthy companies Simply Wall St™ Simply Wall Street Pty Ltd Level 7, 320 Pitt Street, Sydney Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":false,"variant":{"name":"disabled","enabled":false},"flagsReady":false,"flagsError":null}